Therapeutic strategies that restore SEMA3A/3F signaling or inhibit SEMA3C, such as semaphorin analogs, Plexin B1-Fc decoys, and anti-SEMA3C antibodies, have shown promise in reducing tumor growth and neural infiltration in preclinical cancer models [234,235]. This evidence concerns the gene SEMA3C and cancer.